About Transmembrane protein 237
Transmembrane protein 237 (TMEM237) is a protein
from Homo sapiens identified by UniProt accession
Q96Q45, 408 residues long.
MolForge cross-references it against 0 known binders and
24 disease associations.
Target properties
| Protein name | Transmembrane protein 237 |
| UniProt accession | Q96Q45 |
| Gene | TMEM237 |
| Organism | Homo sapiens |
| Length | 408 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (24)
Diseases linked to this target (Open Targets).
- Joubert syndrome · score 0.82
- Joubert syndrome with oculorenal defect · score 0.62
- Joubert syndrome and related disorders · score 0.45
- Meckel syndrome · score 0.43
- Joubert syndrome with renal defect · score 0.37
- upper aerodigestive tract neoplasm · score 0.30
- neurodegenerative disease · score 0.27
- genetic disorder · score 0.19
- hepatocellular carcinoma · score 0.03
- congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96Q45-F1 | alphafold | PREDICTED | 63.64 | — |
Amino-acid sequence (408 residues)
MRTDSGARLE EGHLRPPRAL PPVPSQDDIP LSRPKKKKPR TKNTPASASL EGLAQTAGRR PSEGNEPSTK ELKEHPEAPV QRRQKKTRLP LELETSSTQK KSSSSSLLRN ENGIDAEPAE EAVIQKPRRK TKKTQPAELQ YANELGVEDE DIITDEQTTV EQQSVFTAPT GISQPVGKVF VEKSRRFQAA DRSELIKTTE NIDVSMDVKP SWTTRDVALT VHRAFRMIGL FSHGFLAGCA VWNIVVIYVL AGDQLSNLSN LLQQYKTLAY PFQSLLYLLL ALSTISAFDR IDFAKISVAI RNFLALDPTA LASFLYFTAL ILSLSQQMTS DRIHLYTPSS VNGSLWEAGI EEQILQPWIV VNLVVALLVG LSWLFLSYRP GMDLSEELMF SSEVEEYPDK EKEIKASS
Explore Transmembrane protein 237 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets